Achilles Therapeutics to Present at Upcoming Investor Conferences
Achilles Therapeutics plc (NASDAQ: ACHL) announced its participation in several investor conferences in September 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Achilles Therapeutics plc (NASDAQ: ACHL) announced its participation in several investor conferences in September 2021. The presentations include the Wells Fargo Virtual Healthcare Conference on September 10, the H.C. Wainwright 23rd Annual Global Investment Conference starting September 13, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22. A webcast of the presentations will be available on the Achilles website.
Details
News Market Reaction – ACHL
The recorded move for ACHL in the trading session of this news was -2.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will present at the following investor conferences in September.
- Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021 at 10:40am ET / 3:40pm UK
- H.C. Wainwright 23rd Annual Global Investment Conference available beginning Monday, September 13, 2021 at 7:00am ET / 12:00pm UK
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 8:15am ET / 1:15pm UK
A live and archived webcast of the presentations will be available in the Events & Presentations section of the Achilles website.
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Further information:
Lee M. Stern – VP, IR & External Communications
+1 (332) 373-2634
l.stern@achillestx.com
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.